The global Stem Cell Manufacturing Market is estimated to be valued at US$ 12415.84 Mn in 2023 and is expected to exhibit a CAGR of 13.3% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Overview:
Stem cell manufacturing involves the isolation, purification, expansion and storage of human stem cells derived from different sources such as bone marrow, adipose tissue and human embryos. Stem cell manufacturing is gaining importance owing to potential applications of stem cells in the treatment of various diseases including cardiovascular diseases, diabetes, cancer, etc.
Market key trends:
One of the key trends in the stem cell manufacturing market is increasing adoption of automated cell processing. Automated stem cell processing workflow allows standardized, reproducible and scalable stem cell manufacturing. Automated processing helps streamline manufacturing from cell collection to final storage with minimal human errors and contamination risks. This enhances the quality, safety and efficiency of stem cell manufacturing. Players are focusing on developing automated closed systems for isolation, analysis, cryopreservation and culture of stem cells to meet the increasing demand for cell therapies.
SWOT Analysis
Strength: The stem cell manufacturing market has high growth potential due to increasing investment in R&D for stem cell therapies. There is growing public awareness about stem cell therapies and the potential benefits they offer in treating chronic diseases.
Weakness: The manufacturing process of stem cells is complex and requires stringent protocols and stringent regulatory compliances which increase costs. Lack of availability of skilled researchers can also hamper market growth.
Opportunity: Increasing prevalence of chronic diseases and rise in aging population globally presents significant growth opportunities. Developing economies offer lower costs for clinical trials which attract stem cell manufacturing companies.
Threats: Ethical issues related to stem cell research and lack of regulatory standards pose threats. Stem cell therapies also face challenges in terms of limited clinical research and lack of standardized protocols.
Key Takeaways
The Global Stem Cell Manufacturing Market Size is expected to witness high growth, exhibiting a CAGR of 13.3% over the forecast period, due to increasing investment in developing cell therapies and regenerative medicines.
Regional analysis: North America dominates the global market owing to strong presence of key players and availability of research funds. Asia Pacific is expected to witness fastest growth over the forecast period supported by low-cost clinical trials.
Key players operating in the stem cell manufacturing market are TAKARA BIO Inc., PHARMICELL Co., Ltd., MEDIPOST Co., Holostem Terapie Avanzate S.r.l, Bio-Rad Laboratories, Anterogen Co., Ltd., Osiris Therapeutics, Inc (Smith & Nephew PLC), Minaris Regenerative Medicine (Hitachi Chemical Co., Ltd.), Nikon CeLL Innovation Co. Ltd. (Nikon Corporation), Medinet Co. Ltd., Cell and Gene Therapy Catapult, Bio Elpida, Miltenyi Biotec, Pluristem Therapeutics Inc., Thermo Fischer Scientific, Merck Group, Corning Incorporated, Stem Cell Technologies, Lonza Group, Becton, Dickinson and Company, Sartorius, and Cellular Dynamics (Fujifilm Holdings Corporation, among others.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it